Program
tegoprazan
Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.
Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.
Drug pageTegoprazan: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HK inno.Nits history only | 376 open or running | phase 4since Mar 13, 2020 | Nov 14, 2011 | Jan 31, 2027phase 1 · NCT07853248 |
| Shandong Luoxin Pharmaceutical Group Stockits history only | 70 open or running | phase 3since Jul 9, 2018 | Jan 25, 2018 | none ahead |
| Sebela Pharmaceuticalsits history only | 30 open or running | phase 3since Oct 17, 2022 | Oct 17, 2022 | none ahead |
| Carnot Laboratoriesits history only | 11 open or running | phase 4since May 20, 2025 | May 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 33 earlier studies, Nov 14, 2011 to Aug 11, 2021.
- Jun 9, 2015Named tegoprazanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BLI5100
- Apr 25, 2022Phase 1 study in HealthyHK inno.N · NCT05353010 · 12 enrolled · Korea, Republic of
- Oct 9, 2022Phase 3 study in Helicobacter Pylori InfectionShandong Luoxin Pharmaceutical Group Stock · NCT05577468 · 561 enrolled · China
- Oct 17, 2022Sebela Pharmaceuticals’ first studies: 2 phase 3 studiesNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT05587322, NCT05587309
- Jan 18, 2023Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT05701540 · 338 planned · Korea, Republic of
- Feb 2, 2023Phase 1 study in HealthyHK inno.N · NCT05723510 · 87 enrolled · Korea, Republic of
- May 5, 2023Phase 3 study in Non-Erosive Reflux DiseaseSebela Pharmaceuticals · NCT05890001 · 400 enrolled · United States
- May 10, 2023Phase 1 study in Healthy SubjectsShandong Luoxin Pharmaceutical Group Stock · NCT05883306 · 6 enrolled · China
- May 23, 2023Phase 2 study in Helicobacter Pylori InfectionHK inno.N · NCT05933031 · 381 planned · Korea, Republic of
- Jun 2, 2023Phase 1 study in HealthyShandong Luoxin Pharmaceutical Group Stock · NCT05915871 · 22 enrolled · China
- Dec 1, 2023Phase 1 study in HealthyHK inno.N · NCT06164834 · 48 planned · Korea, Republic of
- Feb 20, 2024Phase 1 study in HealthyHK inno.N · NCT06332638 · 36 planned · Korea, Republic of
- May 20, 2025Carnot Laboratories’ first study: phase 4 study in Gastroesophageal RefluxNew to Carnot LaboratoriesCarnot Laboratories · NCT06991348 · 128 planned · Mexico
- Sep 13, 2026Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455 · 100 planned
- Sep 14, 2026Phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248 · 34 planned · South Korea
Ahead
- Jan 31, 2027Primary completion: phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248
- Jul 31, 2028Primary completion: phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455
TargetBeta
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07853248Healthy Adult Male · South Korea | 1 | Not yet recruiting | HK inno.N | Jan 31, 2027 | 34 |
| NCT07826455Gastroesophageal Reflux | 4 | Not yet recruiting | HK inno.N | Jul 31, 2028 | 100 |
| NCT06991348Gastroesophageal Reflux · Mexico | 4 | Recruiting | Carnot Laboratories | Nov 30, 2025 | 128 |
| NCT06332638Healthy · Korea, Republic of | 1 | By invitation | HK inno.N | Jul 31, 2024 | 36 |
| NCT06164834Healthy · Korea, Republic of | 1 | Not yet recruiting | HK inno.N | Nov 2024 | 48 |
| NCT05915871Healthy · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Apr 28, 2023 | 22 |
| NCT05933031Helicobacter Pylori Infection · Korea, Republic of | 2 | Recruiting | HK inno.N | Dec 31, 2024 | 381 |
| NCT05883306Healthy Subjects · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Jul 21, 2022 | 6 |
| NCT05890001Non-Erosive Reflux Disease · United States | 3 | Completed | Sebela Pharmaceuticals | Oct 8, 2024 | 400 |
| NCT05723510Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 17, 2023 | 87 |
| NCT05701540Gastroesophageal Reflux · Korea, Republic of | 4 | Recruiting | HK inno.N | Dec 31, 2024 | 338 |
| NCT05587322Non-Erosive Reflux Disease · United States | 3 | Completed | Sebela Pharmaceuticals | Oct 13, 2023 | 788 |
| NCT05587309Erosive Esophagitis · United States | 3 | Completed | Sebela Pharmaceuticals | Jun 16, 2025 | 1,250 |
| NCT05577468Helicobacter Pylori Infection · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Sep 30, 2023 | 561 |
| NCT05353010Healthy · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jul 1, 2022 | 12 |
| NCT05010954Duodenal Ulcer · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Sep 28, 2022 | 400 |
| NCT05267743Erosive Reflux Disease · Korea, Republic of | 4 | Completed | HK inno.N | May 25, 2022 | 218 |
| NCT04840550Preventive Peptic Ulcer · South Korea | 3 | Completed | HK inno.N | Jul 1, 2025 | 392 |
| NCT04639804Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 26, 2020 | 60 |
| NCT04494269Hepatic Impairment · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jun 2023 | 28 |
| NCT04309916Erosive Reflux Disease · Korea, Republic of | 4 | Completed | HK inno.N | Nov 30, 2021 | 46 |
| NCT04231136Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 29, 2020 | 19 |
| NCT04221321Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Mar 12, 2020 | 32 |
| NCT04171687Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 7, 2020 | 36 |
| NCT04128917Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Dec 21, 2020 | 102 |
| NCT04066257Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 22, 2019 | 32 |
| NCT04022096Healed Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Jun 23, 2021 | 351 |
| NCT03863938Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Apr 26, 2019 | 12 |
| NCT03814642Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 22, 2019 | 25 |
| NCT03615677Erosive Esophagitis (EE) · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Oct 18, 2019 | 261 |
| NCT03591653Non-Erosive Reflux Disease · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Oct 30, 2019 | 291 |
| NCT03530228Pharmacodynamics · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Aug 2018 | 44 |
| NCT03498456Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Dec 31, 2019 | 284 |
| NCT03458650Healthy · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Apr 23, 2018 | 38 |
| NCT03378284Pharmacodynamics · Korea, Republic of | 1 | Completed | HK inno.N | Dec 23, 2017 | 16 |
| NCT03317223Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Jan 21, 2019 | 350 |
| NCT03043521Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Aug 12, 2015 | 24 |
| NCT03009760Healthy | 1 | Completed | HK inno.N | Apr 2016 | 16 |
| NCT03011996Drug Interaction · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2017 | 60 |
| NCT02995239Erosive Esophagitis · Korea, Republic of | 1 | Completed | HK inno.N | Apr 2015 | 12 |
| NCT03006874Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Mar 24, 2017 | 302 |
| NCT02761512Stomach Ulcer · Korea, Republic of | 3 | Completed | HK inno.N | Jul 26, 2018 | 306 |
| NCT02556021Non-Erosive Reflux Disease · Korea, Republic of | 3 | Completed | HK inno.N | Nov 1, 2016 | 324 |
| NCT02456935Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Jul 2016 | 280 |
| NCT02052336Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jan 2014 | 24 |
| NCT02028663Gastroesophageal Reflux · Korea, Republic of | 2 | Completed | HK inno.N | May 2014 | 206 |
| NCT01830309Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2013 | 24 |
| NCT01473173Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Aug 2012 | 59 |
How it is read
Names in the registry
- “Tegoprazan”, 10 entries
- “Tegoprazan 50 mg”, 5 entries
- “BLI5100”, 3 entries
- “Tegoprazan 50mg”, 3 entries
- “CJ-12420 50mg”, 3 entries
Conditions, from the studies’ own filings
- Esophagitis, 6 studies
- Non-Erosive Reflux Disease, 4 studies
- Gastroesophageal Reflux, 4 studies
- Peptic Ulcer, 1 study
- Duodenal Ulcer, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.